Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sathy V Balu-Iyer

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|February 15, 2011
In vitro immunogenicity risk assessment of therapeutic proteins in preclinical settingPuneet Gaitonde, Sathy V Balu-Iyer
Journal of Pharmaceutical Sciences|January 2, 2019
Immunogenicity of Protein PharmaceuticalsRobert Dingman, Sathy V Balu-Iyer
Journal of Pharmaceutical Sciences|July 20, 2016
Effect of Biophysical Properties of Phosphatidylserine Particle on Immune Tolerance Induction Toward Factor VIII in a Hemophilia A Mouse ModelRadha Ramakrishnan, Sathy V Balu-Iyer
Journal of Pharmaceutical Sciences|November 21, 2014
Anatomical, physiological, and experimental factors affecting the bioavailability of sc-administered large biotherapeuticsAnas M Fathallah, Sathy V Balu-Iyer
Journal of Pharmaceutical Sciences|August 5, 2016
Phosphatidylserine Converts Immunogenic Recombinant Human Acid Alpha-Glucosidase to a Tolerogenic Form in a Mouse Model of Pompe DiseaseJennifer L Schneider, Sathy V Balu-Iyer
Communications Medicine|December 8, 2023
A mechanistic marker-based screening tool to predict clinical immunogenicity of biologicsNicole L Jarvi, Sathy V Balu-Iyer
International Journal of Pharmaceutics|July 8, 2018
Subcutaneous administration of Lyso-phosphatidylserine nanoparticles induces immunological tolerance towards Factor VIII in a Hemophilia A mouse modelFiona Y Glassman, Sathy V Balu-Iyer
Journal of Pharmaceutical Sciences|January 17, 2018
Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic ProteinsMichael R Turner, Sathy V Balu-Iyer
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 1, 2021
Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic ProteinsNicole L Jarvi, Sathy V Balu-Iyer
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 10, 2026
Immunogenicity of Gene and Cell TherapiesKirk Hofman, Priyanka Jangied, Sathy V Balu-Iyer
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
Methods in Molecular Biology (Clifton, N.J.)|February 15, 2011
In vitro immunogenicity risk assessment of therapeutic proteins in preclinical settingPuneet Gaitonde, Sathy V Balu-Iyer
Journal of Pharmaceutical Sciences|January 2, 2019
Immunogenicity of Protein PharmaceuticalsRobert Dingman, Sathy V Balu-Iyer
Journal of Pharmaceutical Sciences|July 20, 2016
Effect of Biophysical Properties of Phosphatidylserine Particle on Immune Tolerance Induction Toward Factor VIII in a Hemophilia A Mouse ModelRadha Ramakrishnan, Sathy V Balu-Iyer
Journal of Pharmaceutical Sciences|November 21, 2014
Anatomical, physiological, and experimental factors affecting the bioavailability of sc-administered large biotherapeuticsAnas M Fathallah, Sathy V Balu-Iyer
Journal of Pharmaceutical Sciences|August 5, 2016
Phosphatidylserine Converts Immunogenic Recombinant Human Acid Alpha-Glucosidase to a Tolerogenic Form in a Mouse Model of Pompe DiseaseJennifer L Schneider, Sathy V Balu-Iyer
Communications Medicine|December 8, 2023
A mechanistic marker-based screening tool to predict clinical immunogenicity of biologicsNicole L Jarvi, Sathy V Balu-Iyer
International Journal of Pharmaceutics|July 8, 2018
Subcutaneous administration of Lyso-phosphatidylserine nanoparticles induces immunological tolerance towards Factor VIII in a Hemophilia A mouse modelFiona Y Glassman, Sathy V Balu-Iyer
Journal of Pharmaceutical Sciences|January 17, 2018
Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic ProteinsMichael R Turner, Sathy V Balu-Iyer
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 1, 2021
Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic ProteinsNicole L Jarvi, Sathy V Balu-Iyer
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 10, 2026
Immunogenicity of Gene and Cell TherapiesKirk Hofman, Priyanka Jangied, Sathy V Balu-Iyer
Pageof 7